Dr Yungan Tao speaks to ecancer about his ESMO presentation on the results from the PembroRad trial.
The randomised trial looked at pembrolizumab vs cetuximab, concomitant with radiotherapy, in locally advanced head and neck squamous cell carcinoma.
Dr Tao reports that while the pembrolizumab arm did not meet the primary endpoint of the trial, fewer toxicities were experienced.
He comments on possible combinations of pembrolizumab with radiotherapy that may be promising to investigate in the future.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.